Forecasts of explosive AI progress predict that what researchers call recursive self-improvement is on the horizon.  But a ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. The above button links to ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

'We really do earnestly believe AI could kill all humans!' ...

Ginkgo Bioworks has pivoted to autonomous lab infrastructure in an attempt to capitalize on emerging AI tailwinds. Read more ...

Alphabet high CapEx spending is prudent given the all-or-nothing nature of the AI race, with data centers retaining value. Read why GOOG stock is a buy.

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...